Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,041 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,668 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06250244 | 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 12 | Peking Union Medical College HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT04913337 |
| Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies |
| unknown |
| Phase 1 / Phase 2 |
| 179 |
| NGM Biopharmaceuticals, IncINDUSTRY |
| 3 |
| Oct 2, 2024 |
| clinicaltrials |
| NCT05684731 | Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer(K19017-004) | unknown | Phase 1 | 30 | Tongji HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06237491 | The Safety and Dosimetry Study of 177Lu-LNC1003 Injection | unknown | Phase 1 | 12 | Yantai LNC Biotechnology Singapore PTE. LTD.INDUSTRY | 0 | Jul 24, 2024 | clinicaltrials |
| NCT04432857 | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | unknown | Phase 1 | 63 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 2 | Jun 27, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT06081686 | Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer | unknown | Phase 1 / Phase 2 | 32 | Sinotau Pharmaceutical GroupINDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05458544 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application(LUCIDA) | unknown | Phase 1 / Phase 2 | 26 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05989724 | A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 150 | Qurgen Inc.INDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06308406 | A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 54 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06344715 | Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. | unknown | Phase 1 | 78 | SL VAXiGENINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06241235 | Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma | unknown | Phase 1 / Phase 2 | 48 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT04766320 | Study on TIL for the Treatment of r/r Gynecologic Tumors | unknown | Phase 1 | 15 | Shanghai 10th People's HospitalOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05472857 | Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression | unknown | Phase 1 | 30 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06281860 | Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration(PITHAC) | unknown | Phase 1 | 39 | Dr Jean Yannis PERENTESOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02730923 | Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)(VICTORIA) | unknown | Phase 1 / Phase 2 | 72 | Centre Leon BerardOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05829057 | The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 | unknown | Phase 1 | 10 | Zhejiang UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04149691 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | unknown | Phase 1 | 42 | Celon Pharma SAINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06223308 | A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 54 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06221774 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | unknown | Phase 1 / Phase 2 | 42 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT02935205 | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 38 | Mamta ParikhOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05732948 | PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer | unknown | Phase 1 | 12 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05580107 | MDPK67b in Patients With Prostate Cancer | unknown | Phase 1 | 15 | Med Discovery SAINDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04097002 | First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | unknown | Phase 1 / Phase 2 | 24 | Orca Therapeutics B.V.INDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06095674 | ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study(ITHACA) | unknown | Phase 1 | 30 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT06065592 | Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms(CAT_PB) | unknown | Phase 1 | 500 | Lebanese UniversityOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06062355 | Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer | unknown | Phase 1 | 9 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Oct 2, 2023 | clinicaltrials |
| NCT03382340 | IMX-110 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 70 | Immix Biopharma Australia Pty LtdINDUSTRY | 2 | Sep 28, 2023 | clinicaltrials |
| NCT06055348 | SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer | unknown | Phase 1 / Phase 2 | 112 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT06006104 | Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer | unknown | Phase 1 / Phase 2 | 49 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Aug 23, 2023 | clinicaltrials |
| NCT05420545 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05468190 | A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T | unknown | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05973149 | Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer | unknown | Phase 1 | 108 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05965141 | Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer | unknown | Phase 1 / Phase 2 | 38 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Jul 28, 2023 | clinicaltrials |
| NCT04678102 | Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)(CREATIVE) | unknown | Phase 1 | 36 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05902247 | Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy(225AcPSMAI&T) | unknown | Phase 1 | 30 | Erasmus Medical CenterOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05607693 | A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects | unknown | Phase 1 | 52 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT05856630 | Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg | unknown | Phase 1 | 24 | Luye Pharma Group Ltd.INDUSTRY | 1 | May 12, 2023 | clinicaltrials |
| NCT05393440 | First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer(CC-OV01) | unknown | Phase 1 | 18 | Zhongnan HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05533203 | Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) | unknown | Phase 1 | 24 | Shanghai Humantech Biotechnology Co. LtdINDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT05620654 | A Phase I Dose-finding Trial of Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin | unknown | Phase 1 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT03540017 | HIPEC After Initial CRS in Patients Who Have Received NACT | unknown | Phase 1 | 15 | Northwell HealthOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT01197625 | Vaccine Therapy in Curative Resected Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Dec 18, 2024source: clinicaltrials